Review

Bioactives of *Momordica charantia* as Potential Anti-Diabetic/Hypoglycemic Agents

Bilin Xu 1,†, Zhiliang Li 1,†, Ting Zeng 2, Jianfeng Zhan 1, Shuzhen Wang 1, Chi-Tang Ho 3 and Shiming Li 1,3,*

1 College of Biology and Agricultural Resources, Huanggang Normal University, Huanggang 438000, China; xubilin@whu.edu.cn (B.X.); swzl@hgnu.edu.cn (Z.L.); swzjf@hgnu.edu.cn (J.Z.); wangshuzhen710@whu.edu.cn (S.W.)
2 College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; mm08901@yahoo.com
3 Department of Food Science, Rutgers University, New Brunswick, NJ 08901, USA; ctho@sebs.rutgers.edu
* Correspondence: shiming@rutgers.edu
† These authors contributed equally to this work.

Abstract: *Momordica charantia* L., a member of the Curcubitaceae family, has traditionally been used as herbal medicine and as a vegetable. Functional ingredients of *M. charantia* play important roles in body health and human nutrition, which can be used directly or indirectly in treating or preventing hyperglycemia-related chronic diseases in humans. The hypoglycemic effects of *M. charantia* have been known for years. In this paper, the research progress of *M. charantia* phytobioactives and their hypoglycemic effects and related mechanisms, especially relating to diabetes mellitus, has been reviewed. Moreover, the clinical application of *M. charantia* in treating diabetes mellitus is also discussed, hoping to broaden the application of *M. charantia* as functional food.

Keywords: *Momordica charantia*; bioactives; hypoglycemic activity; diabetes mellitus; synergistic effect

1. Introduction

Due to globalization, industrialization and changes of human environment, hyperglycemia is widely prevalent [1]. Diabetes mellitus has been estimated to be the fifth leading cause of death globally, characterized by hyperglycemia due to defects in insulin action, insulin secretion, or both [2,3]. Characterized by altered carbohydrate, lipid and protein metabolism, diabetes mellitus is the leading cause of renal, neurological, and gastrointestinal manifestations in developed and developing countries [4–7]. Type 1 diabetes mellitus (T1DM), chiefly genetic, is characterized by disruption of pancreas function and absolute insulin insufficiency [8]. Insulin resistance plays a critical role in the development of type 2 diabetes mellitus (T2DM) and related complications [9]. T2DM is the major type of diabetes mellitus, affecting 90% of overall diabetes patients. Therefore, optimizing diabetes mellitus therapy is a modern critical medical and social challenge [8]. In particular, effective control of postprandial blood glucose levels may play key roles in diabetes care [10].

Many pharmacological approaches have been used to improve hyperglycemia, mainly through stimulating insulin release, increasing glucose transport activity, inhibiting gluconeogenesis, and reducing absorption of glucose from the intestine [10]. Currently, available therapies may be used as monotherapy or in combination to provide better glycemic regulation [11]. In addition to dietary management, hypoglycemic drugs are often used to treat T2DM [8]. However, the available hypoglycemic reagents have inadequate efficacy and some serious mechanism-based side effects, including hypoglycemia, gastrointestinal stimulation, and edema [12,13]. Owing to these severe side-effects of synthetic hypoglycemic drugs, more effective and safer hypoglycemic agents from natural sources are greatly needed [14–18].
Natural phytoconstituents with hypoglycemic effect mainly contain peptides, lipids, glycopeptides, flavonoids, alkaloids, terpenoids, phenolics, glycosides, steroids, carotenoids, tannins, saponins, iridoids, ursolic acid and imidazolines [19]. *Momordica charantia* L., also known as bitter melon or bitter gourd, belonging to the Cucurbitaceae family, is widely distributed in tropical and subtropical regions, such as Asia, South America, Africa, parts of the Amazon basin, and the Caribbean [20]. Notably, *M. charantia* seeds and fruits are rich in proteins, the quality of which meet the amino acids requirements/standards laid down by WHO for preschool children [21]. Due to various health-promoting properties, such as hypoglycemic, anti-cancerous, antimicrobial, antioxidant, antifertility, antimutagenic, antihelminthic, and immunomodulatory activities, *M. charantia* has been used as traditional medicinal plant in treating toothache, gout, jaundice, leprosy, furuncle, dysmenorrhea, piles, pneumonia, psoriasis, diarrhea, eczema, and rheumatism [22–24].

Due to remarkable hypoglycemic properties, *M. charantia* has great potential as an dietary ingredient and in medical foods for diabetic and prediabetic patients, as well as for the regulation of body weight and lipid metabolism [25]. This review discusses the potential applications of *M. charantia* bioactive compounds in the management of hyperglycemia and related chronic diseases, and clarifies the possible action of their mechanisms, hoping to supply valuable references for the development of *M. charantia* bioactives as hypoglycemic agents.

### 2. Bioactive Compounds of *M. charantia* with Hypoglycemic Potentials

As a highly nutritive vegetable, *M. charantia* contains numerous active phytochemicals, including proteins, carbohydrates, fatty acids, essential oils, amino acids, vitamins, phenolic acids, minerals, alkaloids, flavonoids, triterpenoids, quinines, saponins, triterpene glycosides, and other bioactive components [25]. Many types of bioactive compounds with hypoglycemic potentials have been isolated from *M. charantia*, among which cucurbitane-type triterpene glycosides, charantin, and momordicin were the well-studied compounds (Figures 1 and 2). Polypeptide-p, purified from *M. charantia* fruit and seeds, showed effective hypoglycemic activities when administered subcutaneously to langurs, gerbils, and humans [26]. The 68-residue of insulin receptor (IR)-binding protein (mclRBP) and adMc1proteins from *M. charantia* exhibited hypoglycemic effects in mice [27]. The 9cis,11trans,13trans-conjugated linolenic acid (9c,11t,13t-CLN) regulated lipid and glucose homeostasis via inducing acyl CoA oxidase (ACO) activity and serving as peroxisome proliferator activated receptor-α (PPARα) activators [28]. Charantin, momordenol, and momordicilin are important active compounds possessing insulin-like chemical structure and properties [7]. Momordicine II and kuguaglycoside G could also stimulate insulin secretion [29,30].

*M. charantia* triterpenoids (Figure 1) were found to control the balance of blood glucose via increasing adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) activity, which further enhanced glucose uptake and fatty acid oxidation, as well as inhibited lipid synthesis and hepatic glucose output [31]. Momordicosides (Q, R, S, U, and T) and karaviloside XI all exhibited many biologic effects beneficial to diabetes, such as enhancing the entry of inducible glucose into cells and stimulating fatty acid oxidation and glucose disposal [29,32,33]. The 5β,19-epoxy-3β,25-dihydroxyxycarbina-6,23(E)-diene and 3β,7β,25-trihydroxyxycarbina-5,23(E)-dien-19-ol, purified from ether fraction of *M. charantia* methanol extract, showed blood hypoglycemic effects at the dosage of 400 mg/kg in diabetes-induced male ddY mice [33]. Protein tyrosine phosphatase 1B (PTP1B) served as a negative regulator of insulin through the dephosphorylation of the activated insulin receptor, which could be an effective target for the therapy of type 2 diabetes [34]. Cucurbitane-type triterpenoids, such as 25-O-methylkaraviagein D, karaviloside II, and (19R,23E)-5β,19-epoxy-19,25-dimethoxycarbina-6,23-dien-3β-ol, all showed remarkable inhibitory activity against PTP1B and α-amylase (Figure 2) [15].
β,19-epoxy-19,25-dimethoxycucurbita-6,23-dien-3β–ol, all showed remarkable inhibitory activity against PTP1B and α-amylase (Figure 2) [15].

Figure 1. Chemical structure of main *M. charantia* active substance. (A–H) referred to charantin, karaviloside XI, momordenol, momordicoside Q, momordicoside S, momordicoside T, 9c,11t,13t-CLN, and momordicilin, respectively.
Figure 2. Chemical structure of main *M. charantia* cucurbitane-type triterpenoids.
3. Antidiabetic Activity of *M. charantia*

*M. charantia* could effectively combat diabetes mellitus (Table 1). In obese diabetic db/db mice, *M. charantia* fruit water extract alone or together with platycodin-D significantly decreased obesity-related changes, and the water extract:platycodin-D (1:4) showed the most dramatic and synergic obesity-inhibiting effects [35]. In alloxan diabetic albino rats, acetone extract of whole *M. charantia* fruit lowered blood glucose from 13 to 50% after 8–30 days treatment [36]. Administration of *M. charantia* fruit methanol extract for 28 days lowered blood glucose levels in a dose-dependent manner in both normal and diabetic animals [37]. In the normal glucose primed rat model, alcoholic extract of *M. charantia* fruit significantly depressed plasma glucose levels by 10–15% at 1 h [38]. In both normal and streptozotocin-induced diabetic rats, subcutaneous administration of protein extract of *M. charantia* fruit pulp significantly decreased plasma glucose concentrations in a dose-dependent manner [39].

In normal rats, *M. charantia* pulp juice (250 mg/2 mL water) lowered fasting blood glucose levels significantly (*p* < 0.05 at 120 min), and the effect was even more pronounced with saponin-free methanol extract (150 mg/2 mL water) [40]. In diet-induced obesity C57BL/6 mice (male, 8 wk old), freeze-dried *M. charantia* fruit powder was seen to significantly reduce body weight, as the final body weights of mice receiving 10% *M. charantia* powder were almost the same as the control mice [41]. In normoglycemic Sprague-Dawley rats, aqueous extracts of *M. charantia* fruit (100 mg/kg) greatly reduced blood glucose levels [42].

In patients with T2DM, *M. charantia* extracts of unripe fruit could effectively lower the average fasting glucose level in an age- and sex-independent manner, showing no serious adverse events [43]. In a study of 52 individuals with prediabetes, *M. charantia* fruit extracts lowered elevated fasting plasma glucose [44]. Moreover, *M. charantia* fruit pulps at 2000 mg/day showed a modest hypoglycemic effect in patients with T2DM, and fructosamine levels were significantly reduced [45]. Among 112 patients with T2DM, administration of *M. charantia* fruit powder (2 or 4 g/day) significantly improved blood lipids, atherogenic index, body weight, and systolic blood pressure [46].

3.1. Improving Insulin Secretory and Resistance

*M. charantia* fruit extract could significantly increase islet size, number of β-cells, and total β-cell area, and also induce the regeneration of β-cells in the pancreatic islets of diabetic rats [47]. Furthermore, *M. charantia* fruit juice significantly increased the number of pancreatic β cells through reviving β cells and recovering partially destroyed β cells in streptozocin (STZ)-induced diabetic rats, but showed no effect on pancreatic α and δ cells [48]. In alloxan diabetic albino rats, acetone extract of *M. charantia* fruit showed antihyperglycemic activities through stimulating the recovery of pancreatic islet β cells [36]. Saponin-free methanol extract of *M. charantia* pulp juice (150 mg/2 mL water) showed significant hypoglycemic effects both in fasting (*p* < 0.05 at 120 min) and in postprandial states in non-insulin-dependent diabetes mellitus (NIDDM) model rats, through improving the insulin secretory capacity of B cells and enhancing insulin action, indicating the presence of non-sapogenin hypoglycemic compound(s) in *M. charantia* fruit pulp [40].

In MIN6 β-cells, *M. charantia* extracts rich in saponin significantly stimulated insulin secretion [29]. In particular, momordicine II and kuguaglycoside G also stimulated insulin secretion at concentrations of 10 µg/mL and 25 µg/mL, respectively [29]. The dried powder of *M. charantia* fruit pulp could also increase insulin secretion [49]. In INS-1 cells and rat pancreatic islets, *M. charantia* green fruit methanol extract and its ethyl acetate fraction could increase ATP content, augment insulin secretion in a dose-dependent manner, increase serum insulin levels after glucose loading, and decrease blood glucose levels significantly [50]. In MIN6 β-cells, purified momordicoside U (15.8–197.2 µM) moderately enhanced insulin secretion [30]. In both normal and streptozotocin-induced diabetic rats, protein extract of *M. charantia* fruit pulp raised plasma insulin concentrations 2-fold at 4 h following subcutaneous administration [39]. The protein extract of *M. charantia* fruit pulp...
(10 µg/mL) increased insulin secretion in perfused rat pancreases, and exerted insulin secretagogue and insulinomimetic activities to lower blood glucose concentrations [39]. In male high-fat-fed (HFD) Wistar rats, _M. charantia_ fruit extract notably improved insulin sensitivity, and reduced fasting insulin [51].

The mcIRBP exhibited hypoglycemic effects in mice through interaction with insulin receptors (IR) [27]. In particular, the mcIRBP-19 (spanning residues 50–68 of mcIRBP) could enhance the binding of insulin to IR, stimulate phosphorylation of PDK1 and Akt, as well as stimulate the uptake of glucose in cells and clearance of glucose in diabetic mice (Figure 3) [52]. _M. charantia_ fruit extract supplementation together with a high-fat diet (HFD) improved the insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) [51]. In rats fed high fat diets, _M. charantia_ freeze-dried unripe fruit juice (0.75%) could improve insulin resistance, as well as lower serum insulin and leptin [53].

**Figure 3.** Schematic illustrating of _M. charantia_ active substance towards diabetes mellitus.
Table 1. Effects of *M. charantia* active components on diabetes mellitus.

| Active Components                                      | Dose                  | Model                                      | Effect                                                                 | References |
|--------------------------------------------------------|-----------------------|--------------------------------------------|------------------------------------------------------------------------|------------|
| water extract: platycodin-D (1:4)                      |                       | obese diabetic *db/db* mice                | decrease obesity-related changes                                       | [35]       |
| acetone extract of whole fruit                         | 25–75 mg/100 g body  | alloxan diabetic albino rats,              | lower blood glucose, stimulate the recovery of pancreatic islet β cells| [36]       |
| methanol extract of fruit                              | 200–600 mg/kg         | normal and diabetic animals                | lower blood glucose level,                                             | [37]       |
| alcoholic extract of fruit                             | 500 mg/kg             | normal glucose primed rat                  | depress plasma glucose levels, enhance glycogen synthesis in liver     | [38]       |
| protein extract of fruit pulp                          | 5–10 mg/kg            | normal and STZ-induced diabetic rats       | decrease plasma glucose concentrations, raise plasma insulin concentrations| [39]       |
| fruit pulps                                            | 2000 mg/day           | patients with T2DM                         | hypoglycemic effect                                                    | [40]       |
| powder                                                 | 2–4 g/day             | patients with T2DM                         | improve blood lipids, atherogenic index, body weight, and systolic blood pressure, | [41]       |
| fruit                                                   |                       | STZ-induced diabetic rats, male high-fat-fed Wistar rats, rat L6 myotubes, male Sprague-Dawley rats with diabetes | increase number of pancreatic β cells, improve insulin sensitivity, reduce fasting insulin, increase glucose uptakes, improve wound healing, increase diversity and shift overall structure of gut microbiota, stimulate amino acid uptake, normalise structural abnormalities of peripheral nerves, reduce glucose absorptions, improve body mass gain and LDL cholesterol values | [42,43,44,45] |
| Saponin-free methanol extract of juice                 | 150 mg/2 mL water     | NIDDM model rats                           | improve insulin secretory capacity of B cells, enhance insulin action   | [46]       |
| saponin-rich fraction of fruit                         | 125 µg/mL             | MIN6 β-cells                               | stimulate insulin secretion                                           | [47]       |
| dried powder of fruit pulp                             | 2000 mg/day           | patients with T2DM                         | ameliorate diabetes associated CV risk, decrease level of glycosylated hemoglobin, increase insulin secretion | [48,49,50] |
| green fruit methanol extract and ethyl acetate fraction | 15.8–197.2 µM         | INS-1 cells and rat pancreatic islets      | increase ATP content, augment insulin secretion, increase serum insulin levels, decrease blood glucose levels | [51]       |
| Momordicilin                                           |                       | MIN6 β-cells                               | enhance insulin secretion                                             | [52]       |
| mcIRBP                                                 |                       |                                           | block the active site of GSK-3, induce expression of GLUT4, stimulate phosphorylation of PDK1 and Akt, stimulate the uptake of glucose and clearance of glucose, improve insulin resistance, lower serum insulin and leptin, improve oral glucose tolerance, lower body weight and visceral fat mass, raise serum-free fatty acid concentration, reduce adiposity, enhance AMPK activity, stimulate GLUT4 translocation to the cell membrane, enhance fatty acid oxidation and glucose disposal regulate signaling pathways, up-regulate expression level of glucokinase | [53]       |
| freeze-dried unripe fruit juice                        | 0.75%                 | rats fed high fat diets                    |                                                                       | [54]       |
| momordicosides (Q, R, S, and T) and karaviloside XI    |                       | L6 myotubes, 3T3-L1 adipocytes, mice       |                                                                       | [55]       |
| nanoparticles synthesized with filtrate of methanolic extract and silver nitrate | 50 mg/kg              | STZ-induced diabetic rats                  |                                                                       | [56]       |
3.2. Regulating Glucose Uptake

Glucose transporters (GLUT) are widely distributed in body cells, facilitating the maintenance of the blood glucose level in the human body [61,62]. Sodium-coupled glucose transporters (SGLUTs) are scattered across the human body, and the selective inhibition of SGLUT1 could significantly slow postprandial gut uptake of glucose, as well as increase plasma levels of GLP-1 and GIP in healthy volunteers [63,64]. GLUT2 plays bidirectional roles in specific transportation of glucose in hepatocytes, as well as the absorption and reabsorption of glucose from enterocytes and renal tubules particularly [65]. Therefore, GLUT2 is considered as a competent target in treating diabetes mellitus [66]. The potential target proteins in diabetes contain dipeptidyl peptidase-IV (DPP-IV), GLUT, SGLTs, peroxisome proliferator-activated receptors, and α-glucosidase inhibitors [67]. The mcIRBP-19 could induce expression of GLUT4 (Figure 3) [52].

Six peptides (i.e., SMCG, DECC, TTIT, RTTI, ARNL and TVEV) (Figure 4), derived from the hypoglycemic protein adMc1 of M. charantia, were shown to be potential inhibitors of DPP-IV, SGLT1, and GLUT2 receptor proteins [66]. In L6 myotubes and 3T3-L1 adipocytes, momordicosides (Q, R, S, and T) and karaviloside XI could enhance AMPK activity and stimulate GLUT4 translocation to the cell membrane, which is an essential step for inducible glucose entry into cells [32]. In STZ-induced diabetic rats, daily oral administration of M. charantia fruit juice significantly reduced the Na+- and K+-dependent absorptions of glucose by jejunum [54]. Also in STZ-induced diabetic rats, M. charantia fruit juice could, like insulin, regulate glucose uptake into the jejunum membrane brush border vesicles and skeletal muscle cells [54]. In rat L6 myotubes, lyophilized extract of M. charantia fruit juice (5 μg/mL) stimulated the uptake of 14C-D-glucose, but high concentrations (10–200 μg/mL) inhibited the uptake [54]. M. charantia fruit protein extract enhanced glucose uptake into C2C12 myocytes and 3T3-L1 adipocytes, and significantly increased glucose uptake after 4–6 h of incubation in rat adipocytes [39]. Incubation of L6 rat myotubes with M. charantia fruit juice (1, 5 and 10 μg/mL) resulted in time-dependent increases in 3H-deoxy-D-glucose uptakes [55].

![Figure 4. Chemical structure of the main M. charantia peptides derived from the hypoglycemic protein adMc1.](image)

3.3. Improving Glucose Metabolism

Diabetes mellitus is associated with irregular glucose homeostasis, so the effective control of blood glucose level is critical in preventing or reversing diabetic complications.
and improving life quality in diabetic patients [68]. In male HFD Wistar rats, *M. charantia* fruit extract notably improved glucose tolerance [51]. In STZ-induced diabetic rats, alcoholic extract of *M. charantia* fruit improved the oral glucose tolerance, and led to significant reduction in plasma glucose of 26% at 3.5 h [38]. In rats fed high-fat diets, *M. charantia* freeze-dried unripe fruit juice (0.75%) could improve oral glucose tolerance [53]. The hypoglycemic activities of *M. charantia* fruit extracts might partly be due to increased glucose utilization in the liver [38]. *M. charantia* leaf nanoparticles, synthesized with filtrate from methanolic extract with silver nitrate (1 mM), could significantly up-regulate the expression level of glucokinase in diabetic rats [60]. Momordicilin exhibited antidiabetic activities through blocking the active site of glycogen synthase kinase-3 (GSK-3), which can phosphorylate and inactivate glycogen synthase [7]. In normally fed rats, alcoholic extract of *M. charantia* fruit (500 mg/kg) enhanced glycogen synthesis (4–5 fold) from U-14C-glucose in the liver [38].

### 3.4. Modulating Lipid and Amino Acid Metabolism

In male HFD Wistar rats, *M. charantia* fruit extract notably reduced triacylglycerol, cholesterol and epidydimal fat [51]. Momordicoside(s) could enhance fatty acid oxidation and glucose disposal in both insulin-sensitive and insulin-resistant mice [32]. In STZ-induced diabetic rats, *M. charantia* fruit powder (10 or 50 g/kg diet for 6 weeks) could improve body mass gain and low-density lipoprotein (LDL) cholesterol values, which could be dampened by co-administered trivalent chromium (Cr) [56]. In rats fed high-fat diets, *M. charantia* freeze-dried unripe fruit juice (0.75%) could lower body weight and visceral fat mass, raise serum free fatty acid concentration, and reduce adiposity without affecting fat absorption [53].

Microbes inhabiting the gut may play important roles in hosts’ metabolism homeostasis and health maintenance [69–71]. Oral administration of *M. charantia* fruit significantly prevented hyperlipidemia, but the effects substantially diminished when co-treated with antibiotics [57]. In particular, *M. charantia* fruit moderately increased diversity and shifted the overall structure of gut microbiota via enhancing the relative abundance of short-chain fatty acid (SCFAs)-producing genera and increasing fecal SCFAs content [57]. The transplantation of gut flora from *M. charantia* fruit-treated donor mice significantly decreased serum lipids in male recipient mice [57]. In L6 rat myotubes, *M. charantia* fruit juice (1, 5 and 10 µg/mL) enhanced the N-methyl-amino-α-isobutyric acid uptakes in a time-dependent manner, as *M. charantia* fruit juice exerted a hypoglycemic effect partly through stimulating amino acid uptake into skeletal muscle cells like insulin [55].

### 3.5. Protective Effects of *M. charantia*

In STZ-induced diabetic rats, *M. charantia* fruit juice normalized the structural abnormalities of peripheral nerves, including the mean cross-sectional myelinated nerve fibers, axonal area, myelin area, and maximal fiber area [54]. In Cr-co-supplemented type 2 diabetic rats, *M. charantia* fruit powder could decrease Cr content in liver and kidneys through binding of Cr by polyphenol-type compounds [55,56]. In STZ-induced diabetic rats, *M. charantia* leaf nanoparticles (50 mg/kg) could alleviate diabetes nephropathy through regulating SOCS/JAK/STAT and PI3K/Akt/PTEN signaling pathways: levels of Akt, PI3K, TGF-β, JAK2, STAT3 were down-regulated; the expressions of PTEN, SOCS3 and SOCS4 were up-regulated [60]. In type 2 diabetic db/db mice, the gastro-resistant peptide mcIRBP-9 showed anti-inflammatory and reno-protective abilities, as well as controlling blood glucose and HbA1c levels [72]. The mcIRBP-9 could ameliorate diabetic nephropathy through reducing renal vascular leakage and histopathological changes, altering pathways involved in inflammatory and immune responses, as well as improving inflammatory characteristics of mice [72]. In particular, nuclear factor-κB (NF-κB) played an important role in regulating mcIRBP-9-affected immune pathways [72]. In obese and diabetic OLETF rats, treatment with *M. charantia* edible portion (3%) down-regulated the levels of proinflammatory cytokines in liver, muscle and epididymal fats [73]. Administration of dried
powder of *M. charantia* fruit pulp (2000 mg/day) significantly reduced the levels of glycated hemoglobin A1c, 2-h glucose, areas under the curve (AUC) of glucose, weight, fat percentage, body mass index, and waist circumference [49]. In 112 patients with T2DM, *M. charantia* fruit powder ameliorated diabetes-associated cardiovascular risk factors more effectively than glibenclamide [46]. In 40 diabetic patients (over 18 years old), *M. charantia* administration (two capsules, three times a day after meals, for 3 months) slightly decreased levels of glycosylated hemoglobin (hemoglobin A1c or HbA1c) by 0.22% [59]. *M. charantia* active components could reduce oxidative stress, decrease insulin resistance, increase adiposity, modulate glycolysis and gluconeogenesis, as well as lower oxidative status [74].

Diabetic patients often suffer from chronic nonhealing wounds, such as foot ulcers, which often result in amputations [75–77]. In diabetic patients, hyperglycemia can cause arteries to narrow, result in poor oxygenation of wound tissue, and delay wound repair and regeneration [58,78]. Moreover, the wound-healing response can be further compromised by chronic hyperglycemia-induced damage to both the peripheral nerves and the immune system [58,79]. Diabetes also has deleterious effects on granulation tissue cells, especially fibroblasts and endothelial cells [80]. In male Sprague-Dawley rats with diabetes, *M. charantia* fruit appeared to benefit the formation of wound granulation tissue, as distinct cellular layers were well-formed [75]. Moreover, *M. charantia* fruit treatment increased angiogenesis in diabetic granulation tissue, which was marked by abundant microvessels and large blood vessels [58]. In particular, locally applied *M. charantia* fruit extract could prevent regression of granulation tissue and blood vessels, and improve wound healing in diabetic wounds, showing no effect on systemic blood glucose levels or insulin receptor substrate 1 [58].

3.6. Inhibitory Effects of Related Enzymes

The α-glucosidase, located in the brush-border membranes of human intestinal cells, is involved in carbohydrate metabolism and the post-translational processing of glycoprotein [81]. The α-amylase, an important secretory product generated by the pancreas and salivary glands, can catalyze the initial step of starch hydrolysis to a mixture of oligosaccharides through cleaving the α-D (1–4) glycosidic bonds [82,83]. In particular, α-glucosidase and α-amylase have long been proposed as candidate drug targets for the modulation of postprandial hyperglycemia [84].

As natural inhibitors of α-glucosidase and α-amylase, *M. charantia* may be used as auxiliary hypoglycemic functional foods or drugs (Figure 5). Three cucurbitane-type triterpenoids, including 25-O-methylkaraviagein D, karaviloside II, and (19R,23E)-5β,19-epoxy-19,25-dimethoxy cucurbita-6,23-dien-3β-ol, could all inhibit α-glucosidase activity [15]. 25-O-Methylkaraviagein D showed remarkable inhibitory activity against PTP1B and α-amylase [15]. Capsules containing *M. charantia* extract also exerted anti-obesity activities through selectively and dose-dependently inhibiting the activity of 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1), which is a microsomal enzyme converting glucocorticoid receptor-inert cortisone to active cortisol in metabolic tissues [85].

3.7. Regulation of Signal Pathways

AMPK plays multiple critical roles in the body’s overall metabolic balance, response to exercise, hormonal stimulation, nutritional stress, as well as glucose-lowering drugs metformin and rosiglitazone [10,86]. AMPK consists of a catalytic α subunit and two non-catalytic subunits (β and γ), forming active 1:1:1 heterotrimer. Moreover, the activation of AMPK can induce the expression of PPARα and carnitine palmitoyltransferase I (CPT-1), which further increase fatty acid oxidation and improve insulin sensitivity [87]. In L6 myotubes and LKB1-deficient HeLa cells, *M. charantia* triterpenoids increased AMPK activity by 20–35% through regulating the upstream kinase CaMKKβ in a Ca2+-independent manner [31]. As an AMPK activator, *M. charantia* triterpenoids could increase the expression of AMPK, and further control the balance of blood glucose (Figure 5).
3.7. Regulation of Signal Pathways

AMPK plays multiple critical roles in the body’s overall metabolic balance, response to exercise, hormonal stimulation, nutritional stress, as well as glucose-lowering drugs metformin and rosiglitazone [10,86]. AMPK consists of a catalytic $\alpha$ subunit and two non-catalytic subunits ($\beta$ and $\gamma$), forming active 1:1:1 heterotrimers. Moreover, the activation of AMPK can induce the expression of PPAR$\alpha$ and carnitine palmitoyltransferase I (CPT-1), which further increase fatty acid oxidation and improve insulin sensitivity [87]. In L6 myotubes and LKB1-deficient HeLa cells, M. charantia triterpenoids increased AMPK activity by 20–35% through regulating the upstream kinase CaMKK$\beta$ in a Ca$^{2+}$-independent manner [31]. As an AMPK activator, M. charantia triterpenoids could increase the expression of AMPK, and further control the balance of blood glucose (Figure 5).

PPARs could be activated by a ligand, heterodimerize with retinoid X receptor, binding to a peroxisome proliferator responsive element (PPRE), and promote transcription of target genes participating in lipid catabolism. Therefore, PPARs play important roles in regulating lipid and glucose homeostasis through genomic action [88]. The 9c,11t,13t-CLN, isolated from wild M. charantia fruit, could significantly induce ACO activity in a peroxisome proliferator-responsive murine hepatoma cell line (H4IIEC3) [28]. As a PPAR$\alpha$ activator, 9c,11t,13t-CLN regulated lipid and glucose homeostasis through PPAR$\alpha$ signaling pathways in vivo [28]. In obese and diabetic OLETF rats, treatment with M. charantia edible portion (3%) significantly improved glucose tolerance and insulin sensitivity via inhibiting NF-$\kappa$B and JNK pathways: the levels of phospho-insulin receptor substrate-1 (Tyr612) and phospho-Akt (Ser473) were increased; the activation of NF-$\kappa$B in liver and muscle was decreased [73].

4. Challenges and Perspectives

M. charantia has received considerable attention in biological and biomedical research due to its remarkable biological activities, especially its antidiabetic/hypoglycemic effects. M. charantia is usually served in one of four dosage forms (fruit juice, entire fruit, freeze-dried powder, or capsule), the preparations are mainly crude extracts (extracted with water, ethanol, or methanol) and the effective monomer components are extracted from fruit, seeds, and leaves [89]. In particular, the typical hypoglycemic activities are mainly attributed to proteins/peptides, polysaccharides, phenolic compounds, triterpenoids, alkaloids, and charantins [90,91]. As one of the most important global health problems,
diabetes mellitus could be treated with several *M. charantia*-derived bioactive compounds, mainly through inhibiting α-glucosidase and α-amylase, activating AMPK, JNK, and Akt signal pathways, activating PTP1B activities, and inhibiting the formation of advanced glycation end-products (AGE). The modulation of gut microbiota is essential for the hypoglycemic and anti-hyperlipidemic activities of *M. charantia*. *M. charantia* fruit juice has multiple influences on glucose and lipid metabolism, strongly counteracting the untoward effects of high-fat diets. Furthermore, antioxidant and anti-inflammatory activities also greatly contribute to its anti-hyperglycemic properties. Long-term oral administration of *M. charantia* fruit extracts at appropriate dosages may benefit in improving diabetes. Identification of potential mechanism(s) by which *M. charantia* improves insulin sensitivity and insulin signaling may supply new therapeutic targets for the treatment of obesity/dyslipidemia-induced insulin resistance.

Traditional *M. charantia* remedies have supplied sources of useful hypoglycemic agents, but should continue to be investigated for possible drug alternatives. In vitro and animal studies have suggested the remarkable hypoglycemic activity of *M. charantia*, but limited human research is available to support its usage. *M. charantia* has traditionally been used for treating diabetes, but some clinical trials show conflicting results. In addition, very limited-quality evidence has shown that *M. charantia* adjunct preparations could improve glycemic control in T2DM patients [92]. Moreover, no large clinical trial has been performed on the efficacy and safety of *M. charantia* preparation. Therefore, rigorous research focusing on standardizing *M. charantia* formulation is greatly needed, as well as clinical trials with adequate sample size to determine its efficacy and safety. Diabetes mellitus is also associated with an increase in sialic acid concentration, but ingestion of *M. charantia* fruit juice (55 mL/24 h) showed no effect on levels of serum sialic acid in NIDDM patients [93–95]. Moreover, diabetes mellitus is also associated with disruption of biorhythms, but no related research was available for active components of *M. charantia* [8]. Dysfunction of bone marrow-derived endothelial progenitor cells contributes to poor vasculogenesis in diabetes mellitus [96]. However, the effect of *M. charnartia* active components on bone marrow-derived endothelial progenitor cells is not well understood and needs to be studied in more depth. Moreover, the effect of *M. charantia* active components on protein kinase C is not well understood, and is vital when considering diabetic vascular complications [97].

Due to the interaction of drugs within in vivo systems, rational drug use should consider medical, biological, and pharmaceutical factors to ensure high bioavailability and efficacy. In particular, the most active candidates against diabetes mellitus will be determined through measuring many biochemical parameters, including fasting blood glucose, lipid profile, insulin, glycosylated hemoglobin, serum urea and creatinine, plasma alanine and aspartate transaminases, as well as microscopical examinations of pancreatic sections. Moreover, the gastrointestinal resistance of *M. charantia* bioactive compounds and their thermal tolerance in vivo also need to be better understood. Therefore, further study is greatly needed to investigate the detailed hypoglycemic mechanism and possible linkage to unexpected side effects, aiming to establish a safety guideline for the consumption of *M. charantia*-derived products.

**Author Contributions:** Conceptualization, B.X., Z.L. and S.L.; writing—original draft preparation, B.X. and Z.L.; writing—review and editing, T.Z., J.Z. and S.W.; visualization, B.X. and Z.L.; supervision, C.-T.H. and S.L.; funding acquisition, S.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research reported in this paper was funded by a grant from Hubei Province, China (2019ABA100), Open Fund of the Hubei Key Laboratory of Economic Forest Germplasm Improvement and Resources Comprehensive Utilization (2019S2103), and funding from Assessment and Comprehensive Utilization of Characteristic Biological Resources in Dabie Mountains (4022019006).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.
Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AGE  advanced glycation end products  
AMPK  Adenosine 5′-monophosphate (AMP)-activated protein kinase  
adMc1  anti-hyperglycemic protein of *M. charantia*  
AUC  areas under the curve  
9c,11t,13t-CLN  9cis,11trans,13trans-conjugated linolenic acid  
CPT-1  carnitine palmitoyltransferase I  
Cr  chromium  
DPP-IV  dipeptidyl peptidase-IV  
GLUT  Glucose transporters  
GLP-1  glucagon-like peptide 1  
GIP  glucose-dependent insulintropic peptide  
HFD  high-fat-fed  
IDDM  insulin-dependent diabetes mellitus  
IR  insulin receptor  
IRS-1  insulin receptor substrate-1  
NF-κB  nuclear factor-κB  
NIDDM  non-insulin-dependent diabetes mellitus  
PDK1  protein kinase-1  
STZ  streptozocin  
T1DM  Type 1 diabetes mellitus  
T2DM  Type 2 diabetes mellitus  
mIRBP  *M. charantia* insulin receptor (IR)-binding protein  
PPARα  Peroxisome proliferator activated receptor α  
PTP1B  protein tyrosine phosphatase 1B  
PPRE  peroxisome proliferator responsive element  
SCFAs  short-chain fatty acid  
SGLUTs  Sodium-coupled glucose transporters  
SGLT1  sodium dependent glucose transporter 1  
TAG  triacylglycerol

References

1. Xiao, J.B.; Högger, P. Dietary polyphenols and type 2 diabetes: Current insights and future perspectives. *Curr. Med. Chem.* 2015, 22, 23–38. [CrossRef] [PubMed]
2. Roglic, G.; Unwin, N.; Bennett, H.; Mathers, C.; Tuomilehto, J.; Nag, S.; Connolly, V.; King, H. The burden of mortality attributable to diabetes: Realistic estimates for the year 2000. *Diabetes Care* 2005, 28, 2130–2135. [CrossRef] [PubMed]
3. ADA. Classification and diagnosis of diabetes. *Diabetes Care* 2015, 40, S11–S24.
4. Zhao, Y.; Liu, Y.J.; Yi, F.Z.; Zhang, J.; Xu, Z.H.; Liu, Y.H.; Tao, Y. Type 2 diabetes mellitus impaired nasal immunity and increased the risk of hyposmia in COVID-19 mild pneumonia patients. *Int. Immunopharmacol.* 2021, 93, 107406. [CrossRef]
5. Salamone, D.; Rivellese, A.A.; Vetrani, C. The relationship between gut microbiota, short-chain fatty acids and type 2 diabetes mellitus: The possible role of dietary fibre. *Acta Diabetol.* 2021, 58, 1131–1138. [CrossRef]
6. Karagz, I.K.; Karagz, A.; Zkalayc, F.; Dogan, C.; Kocabay, G.; Elbay, A. Relation between platelet reactivity levels and diabetic retinopathy stage in patient with type 2 diabetes mellitus by using multiplate whole blood aggregometry. *Semin. Ophthalmol.* 2021, 36, 392–399. [CrossRef]
7. Hazarika, R.; Parida, P.; Neog, B.; Yadav, R.N. Binding energy calculation of GSK-3 protein of human against some anti-diabetic compounds of *Momordica charantia* Linn (bitter melon). *Bioinformation* 2012, 8, 251–254. [CrossRef]
8. Bunyatyan, N.D.; Bukhtiyarova, I.P.; Drogozov, S.Z.; Kononenko, A.V.; Olefir, Y.V.; Prokof’ev, A.B.; Proskurina, I.A.; Goryachev, D.V. Influence of human biorhythms on the blood glucose level and the efficacy of hypoglycemic drugs (review). *Pharm. Chem. J.* 2017, 51, 399–401. [CrossRef]
9. Lee, S.H.; Min, K.H.; Han, J.S.; Lee, D.H.; Park, D.B.; Jung, W.K.; Park, P.; Jeon, B.T.; Kim, S.K.; Jeon, Y.J. Effects of brown alga, Ecklonia cava on glucose and lipid metabolism in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus. *Food Chem. Toxicol.* 2012, 50, 575–582. [CrossRef]
10. Zhao, C.; Yang, C.F.; Liu, B.; Lin, L.; Sarker, S.D.; Nahar, L.; Yu, H.; Cao, H.; Xiao, J.B. Bioactive compounds from marine macroalgae and their hypoglycemic benefits. *Trends Food Sci. Technol.* 2018, 72, 1–12. [CrossRef]
10. Khan, V.; Najmi, A.K.; Akhtar, M.; Aqil, M.; Mujeed, M.; Pillai, K.K. A pharmacological appraisal of medicinal plants with anti-diabetic potential. J. Pharm. Biomed. Sci. 2012, 4, 27–42. [PubMed]

11. Lee, S.H.; Kang, N.; Kim, E.A.; Heo, S.J.; Moon, S.H.; Jeon, B.T.; Jeon, Y.J. Antidiabetogenic and antioxidative effects of octaphlorel a isolated from the brown algae Ishige fociaceae in streptozotocin-induced diabetic mice. Food. Sci. Biotechnol. 2014, 23, 1261–1266. [CrossRef]

12. Vinayagam, R.; Xiao, J.B.; Xu, B.J. An insight into anti-diabetic properties of dietary phytochemicals. Phytochem. Rev. 2017, 16, 535–553. [CrossRef]

13. Yue, J.; Xu, J.; Cao, J.; Zhang, X.S.; Zhao, Y.Q. Cucurbitane triterpenoids from Momordica charantia and their inhibitory activity against α-glucosidase, α-amylase and protein tyrosine phosphorylase 1B (PTP1B). J. Funct. Foods. 2017, 37, 624–631. [CrossRef]

14. Mar, K.; Fassnacht, M.; Führer-Sakel, D.; Honegger, J.B.; Weber, M.M.; Kroiss, M. The diagnosis and management of endocrine side effects of immune checkpoint inhibitors. Disch. Arztebl. Int. 2021, 118, 3372917.

15. Preiato, V.L.; Salvagni, S.; Ricci, A.; Ardizzoni, A.; Pelusi, C. Diabetes mellitus induced by immune checkpoint inhibitors: Type 1 diabetes variant or new clinical entity? review of the literature. Rev. Endocr. Metab. Dis. 2021, 22, 337–349. [CrossRef]

16. Fauchier, L.; Fauchier, G.; Bisson, A.; Bodin, A.; Herbert, J.; Angoulvant, D.; Ducluzeau, P.H.; Lip, G.Y.H. Antidiabetic drugs use and new-onset atrial fibrillation in patients with diabetes mellitus. Eur. Heart J. 2021, 42, ehab724.0457. [CrossRef]

17. Qin, W.; Zhang, Y.; Li, Z.; Li, Y.; Li, Z.; Gao, Y.; Fan, H.; Hu, Y.; Yan, J.; Wang, S.; Li, Y.; Wu, D.; et al. Hypoglycemic activity of polysaccharide isolated from bitter melon associated with activation of the AMPK pathway. Int. J. Biol. Macromol. 2021, 187, 1096–1103. [CrossRef]

18. Jia, S.; Shen, M.; Zhang, F.; Xie, J.H. Recent advances in Momordica charantia: A natural healthy vegetable. Int. J. Food Prop. 2018, 21, 1270–1290. [CrossRef]

19. Iseli, T.; Noble, T.; Zeng, X.Y.; Cooney, G.J.; Kraegen, E.W.; Yao, S.; Ye, Y.; James, D.E.; Ye, J.M. Activation of AMPK by bitter melon triterpenoids involves CaMKK. PLoS ONE 2013, 8, e62309. [CrossRef] [PubMed]

20. Li, Y.; Li, J.; Wang, S.; Wang, L.; Li, Y.; He, Y.; Li, Z.; Wang, Z.; Li, Y.; Wu, D.; et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. J. Agric. Food Chem. 2014, 62, 8952–8961. [CrossRef] [PubMed]

21. Jia, S.; Shen, M.; Zhang, F.; Xie, J.H. Recent advances in Momordica charantia: Functional components and biological activities. Int. J. Mol. Sci. 2017, 18, 2555. [CrossRef] [PubMed]

22. Tang, M.J.; Wei, X.; Chen, L.; Wei, Y.; Liu, J.J.; Hsiang, C.Y. Fractionation and identification of 9c, 11t, 13t-conjugated octaphlorethol a isolated from the brown algae Ishige foliacea in streptozotocin-induced diabetic mice. Food. Sci. Biotechnol. 2018, 8, 1749–1762. [CrossRef]

23. Khanna, P.; Jain, S.C.; Panagariray, A.; Dixit, V.P. Hypoglycemic activity of polypeptide-p from a plant source. J. Nat. Prod. 1981, 44, 648–655. [CrossRef]

24. Lo, H.Y.; Ho, T.Y.; Li, C.C.; Chen, J.C.; Liu, J.J.; Hsiang, C.Y. A novel insulin receptor-binding protein from Momordica charantia enhances glucose uptake and glucose clearance in vitro and in vivo through triggering insulin receptor signaling pathway. J. Agric. Food Chem. 2014, 62, 8952–8961. [CrossRef] [PubMed]

25. Chuang, C.Y.; Hsu, C.; Chao, C.Y.; Wein, Y.S.; Kuo, Y.H.; Huang, C.J. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARa in bitter gourd (Momordica charantia L.). J. Biomed. Sci. 2006, 13, 763–772. [CrossRef]

26. Keller, A.C.; Ma, J.; Akhtar, M.; Aqil, M.; Mujeed, M.; Pillai, K.K. A pharmacological appraisal of medicinal plants with anti-diabetic potential. J. Pharm. Biomed. Sci. 2012, 4, 27–42. [PubMed]

27. Lee, S.H.; Kang, N.; Kim, E.A.; Heo, S.J.; Moon, S.H.; Jeon, B.T.; Jeon, Y.J. Antidiabetogenic and antioxidative effects of octaphlorel a isolated from the brown algae Ishige fociaceae in streptozotocin-induced diabetic mice. Food. Sci. Biotechnol. 2014, 23, 1261–1266. [CrossRef]

28. Tan, H.F.; Gan, C.Y. Polysaccharide with antioxidant, α-amylase inhibitory and ace inhibitory activities from the bitter melon. Int. J. Biol. Macromol. 2016, 85, 487–496. [CrossRef] [PubMed]

29. Saini, R.K.; Assefa, A.D.; Keum, Y.S. Fatty acid and carotenoid composition of bitter melon (Momordica charantia L.) seed arils: A potentially valuable source of lycopene. J. Food Meas. Charact. 2017, 11, 1266–1273. [CrossRef]

30. Wang, S.; Li, Z.; Yang, G.; Ho, C.; Li, S. Momordica charantia: A popular health-promoting vegetable with multifunctionality. Food. Sci. Biotechnol. 2017, 8, 1749–1762. [CrossRef]

31. Iseli, T.; Noble, T.; Zeng, X.Y.; Cooney, G.J.; Kraegen, E.W.; Yao, S.; Ye, Y.; James, D.E.; Ye, J.M. Activation of AMPK by bitter melon triterpenoids involves CaMKKβ. PLoS ONE 2013, 8, e62309. [CrossRef] [PubMed]

32. Tian, M.J.; Ye, J.M.; Turner, N.; Hohnen-Behrens, C.; Ke, C.Q.; Tang, C.P.; Chen, T.; Weiss, H.C.; Gesing, E.R.; Rowland, A.; et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol. 2008, 15, 263–273. [CrossRef] [PubMed]
39. Yibchok-Anun, S.; Adisakkwattana, S.; Yao, C.Y. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. *Biol. Pharm. Bull.* 2006, 29, 1126–1131. [CrossRef]

40. Ali, L.; AzadKan, K.; Rouf Mamun, M.I.; Mosihuzzaman, M.; Nahar, N.; Nur-e-Alam, M.; Rokeya, B. Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of *Momordica charantia* on normal and diabetic model rats. *Plant. Med.* 1993, 59, 408–412. [CrossRef]

41. Pina, F.; Brown, A.; Luebecke, E.; Perkins-veazie, P.; Clarke, S.; Kuvibidila, S.; Hill, M.; Linghtfoot, S.; Smith, B.; Lucas, E. *Momordica charantia* improves body weight and glucose tolerance in mice fed high fat diet. *FASEB J.* 2009, 23, 563–567. [CrossRef]

42. Burnett, A.A.J.; Singh, P.D.; Simon, O.; Mckoy, M.L.G. Effect of acute administration of *Momordica charantia* fruit extract on blood glucose levels of normoglycemic rats. *Biol. Trace Elem. Res.* 2011, 25, 889–890.

43. Kim, S.K.; Jung, J.; Jung, J.H.; Yoonb, N.A.; Kangb, S.S.; Robb, G.S.; Haehma, J.R. Hypoglycemic efficacy and safety of *Momordica charantia* (bitter melon) in patients with type 2 diabetes mellitus. *Complement. Ther. Med.* 2020, 52, 102524. [CrossRef] [PubMed]

44. Krawinkel, M.B.; Ludwig, C.; Swai, M.E.; Yang, R.Y.; Chun, K.P.; Habicht, S.D. Bitter gourd reduces elevated fasting plasma glucose levels in prediabetics in Tanzania. *J. Ethnopharmacol.* 2018, 216, 1–7. [CrossRef]

45. Fuangchan, A.; Sonthisombat, P.; Seubnukarn, T.; Chanouan, P.; Chotchaisuwat, P.; Sirigulsatien, V.; Lngkaninan, K.; Plianbangchang, P.; Haines, S.T. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. *J. Ethnopharmacol.* 2011, 134, 422–428. [CrossRef]

46. Rahman, I.U.; Khan, R.; Bashir, M. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. *Nutr.* 2015, 14, 13. [CrossRef]

47. Cortez-Navarrete, M.; Méndez-Del Villar, M.; Ramos-González, E.J.; Pérez-Rubio, K.G. *Momordica Charantia*: A Review of Its Effects on metabolic diseases and mechanisms of action. *J. Med. Food* 2021, 24, 1017–1027. [CrossRef]

48. Ahmed, I.; Adeghate, E.; Sharma, A.K.; Pallot, D.J.; Singh, B. Efects of *Momordica charantia* fruit juice on islet morphology in the pancreas of the streptozotocin- diabetic rat. *Diabetes. Res. Clin. Pr.* 1998, 40, 145–151. [CrossRef]

49. Cortez-Navarrete, M.; Martinez-Abdus, E.; Pérez-Rubio, K.G.; Gonzalez-Ortiz, M.; Villar, M.M.D. *Momordica charantia* Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus. *J. Med. Food.* 2018, 21, 672–677. [CrossRef]

50. Shimada, T.; Kato, F.; Dwijayanti, D.R.; Nagata, T.; Kinoshita, A.; Okuyama, T.; Nishizawa, M.; Mukai, E. Bitter melon fruit extract enhances intracellular ATP production and insulin secretion from rat pancreatic β-cells. *Br. J. Nutr.* 2022, 127, 377–383. [CrossRef]

51. Sridhar, M.G.; Vinayagamoorthy, R.; Arul Suyambunathan, V.; Bobby, Z.; Selvaraj, N. Bitter gourd (*Momordica charantia*) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. *Br. J. Nutr.* 2008, 99, 806–812. [CrossRef] [PubMed]

52. Lo, H.Y.; Li, C.C.; Ho, T.Y.; Hsiang, C.Y. Identification of the bioactive and consensus peptide motif from *Momordica charantia* insulin receptor-binding protein. *Food Chem.* 2016, 204, 298–305. [CrossRef]

53. Chen, Q.; Chan, L.L.; Li, E.T.S. Bitter melon (*Momordica charantia*) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. *J. Nutr.* 2003, 133, 1088–1093. [CrossRef] [PubMed]

54. Ahmed, I.; Adeghate, E.; Cummings, E.; Singh, J. Beneficial effects and mechanism of action of *Momordica charantia* juice in the treatment of streptozotocin-induced diabetes mellitus in rat. *Mol. Cell. Biochem.* 2004, 261, 63–70. [CrossRef] [PubMed]

55. Cummings, E.; Hundal, H.S.; Wackerhage, H.; Belle, M.; Adeghate, E.; Singh, J. *Momordica charantia* fruit juice stimulates glucose and amino acid uptakes in l6 myotubes. *Mol. Cell. Biochem.* 2004, 261, 99–104. [CrossRef]

56. White, P.E.; Król, E.; Szewengiel, A.; Tubacka, M.; Szczepankiewicz, D.; Staniek, H.; Vincent, J.B.; Krejpcio, Z. Effects of bitter melon and a chromium propionate complex on symptoms of insulin resistance and type 2 diabetes in rat models. *J. Med. Food.* 2021, 19, 1013–1026. [CrossRef]

57. Zhang, F.; Zhang, X.; Yu, J.; Tan, Y.; Guo, P.; Wu, C.M. The gut microbiota confers the lipid-lowering effect of bitter melon (*Momordica charantia*) L in high-fat diet (HFD)-induced hyperlipidemic mice. *Biomed. Pharmacother.* 2020, 131, 110667. [CrossRef]

58. Singh, R.; Garcia-Gomez, I.; Gudehthlu, K.P.; Singh, A.K. Bitter melon extract promotes granulation tissue growth and angiogenesis in the diabetic wound. *Adv. Skin Wound Care 2017*, 30, 16–26. [CrossRef]

59. Dans, A.M.L.; Villarruz, M.V.C.; Jimeno, C.A.; Javelosa, M.A.U.; Chua, J.; Bautista, R.; Velez, G.G.B. The effect of *Momordica charantia* capsule preparation on glycemic control in Type 2 Diabetes Mellitus needs further studies. *J. Clin. Epidemiol.* 2007, 60, 554–559. [CrossRef]

60. Elekofehinti, O.O.; Oyedokun, V.O.; Iwaloye, A.; Lawal, A.O.; Ejelou, O.C. *Momordica charantia* silver nanoparticles modulate SOCS/JAK/STAT and P13K/ AKT/PTEN signalling pathways in the kidney of streptozotocin-induced diabetic rats. *J. Diabetes Metab. Dis.* 2021, 20, 245–260. [CrossRef] [PubMed]

61. Duddela, S.; Nataraj Sekhar, P.; Padmavati, G.V.; Banerjee, A.K.; Murty, U.S.N. Probing the structure of human glucose transporter 2 and analysis of protein ligand interactions. *Med. Chem. Res.* 2010, 19, 836–853. [CrossRef]

62. Guillam, M.T.; Hümmler, E.; Schaerer, E.; Wu, J.Y.; Birnbaum, M.J.; Beermann, F.; Schmidt, A.; Deriaz, N.; Thorens, B. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking glu-2. *Nat. Genet.* 1997, 17, 327–330. [CrossRef] [PubMed]

63. Barranco, C. SGLT2 blockers in T2DM. *Nat. Rev. Cardiol.* 2018, 15, 255. [CrossRef] [PubMed]

64. Dobbins, R.L.; Greenway, F.L.; Chen, L.; Liu, Y.; Breed, S.L.; Andrews, S.M.; Wald, J.A.; Walker, A.; Smith, C.D. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. *Am. J. Physiol. - Gastrointest. Liver Physiol.* 2015, 308, G946–G954. [CrossRef] [PubMed]
65. Rhodes, R.S.; Snyder, A.; Rajendran, V.M.; Coon, S. GLUT2 proteins are regulated by the AKT pathway under diabetic conditions in intestinal epithelial cells. *FASEB J.* 2020, 34, 1. [CrossRef]

66. Mabrouk, H.S.; Mehmood, R.; Bukhari, S.A.; Afzal, G.; Arif, R. Investigation of hypoglycemic peptides derived from conserved regions of admc1 to reveal their antidiabetic activities. *BioMed Res. Int.* 2021, 2021, 5550180. [CrossRef]

67. Kumar, V.; Sharma, K.; Ahmed, B.; Al-Abbasi, F.A.; Anwar, F.; Verma, A. Deconvoluting the dual hypoglycemic effect of wedelolactone isolated from Wedelia calendulacea: Investigation via experimental validation and molecular docking. *RSC Adv.* 2018, 8, 18180–18196. [CrossRef]

68. Larsson, J.; Eneroth, M.; Apelqvist, J.; Stenstrom, A. Sustained reduction in major amputations in diabetic patients: A 26-year, 628 amputations in 461 patients in a defined population over a 20-year period. *Diabetes Care* 2013, 36, 2560–2567. [CrossRef] [PubMed]

69. Mahrosh, H.S.; Mehmood, R.; Bukhari, S.A.; Afzal, G.; Arif, R. Investigation of hypoglycemic peptides derived from conserved regions of admc1 to reveal their antidiabetic activities. *BioMed Res. Int.* 2021, 2021, 5550180. [CrossRef]

70. Cani, P.D.; Everard, A. Talking microbes: When gut bacteria interact with diet and host organs. *Mol. Nutr. Food Res.* 2016, 60, 58–66. [CrossRef]

71. Musso, G.; Gambino, R.; Cassader, M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. *Annu. Rev. Med.* 2012, 62, 361–380. [CrossRef] [PubMed]

72. Liao, F.Y.; Lo, H.Y.; Liu, I.C.; Lo, L.C.; Hsiang, C.Y.; Ho, T.Y. A gastro-resistant peptide from *Momordica charantia* improves diabetic nephropathy in db/db mice via its novel reno-protective and anti-inflammatory activities. *Food Funct.* 2022, 13, 1822–1833. [CrossRef] [PubMed]

73. Yang, S.J.; Choi, J.M.; Park, S.E.; Rheec, E.J.; Lee, W.Y.; Oh, K.W.; Park, S.W.; Park, C.Y. Preventive effects of bitter melon (*Momordica charantia*) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. *J. Nutr. Biochem.* 2015, 26, 234–240. [CrossRef] [PubMed]

74. Krawczyk, M.; Burzynska-Pedziwiatr, I.; Wozniak, L.A.; Bukowiecka-Matusiak, M. Evidence from a Systematic Review and Meta-Analysis Pointing to the Antidiabetic Effect of PolypHEN-RICH Plant Extracts from *Gymnema montanum*, *Momordica charantia* and *Moringa oleifera*. *Curr. Issues Mol. Biol.* 2022, 44, 699–717. [CrossRef]

75. Moulik, P.K.; Mtonga, R.; Gill, G. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. *Diabetes Care* 2003, 26, 491–494. [CrossRef] [PubMed]

76. Ghanassia, E.; Villon, L.; Tdd, J.F.; Boegner, C.; Avignon, A.; Sultan, A. Long-term outcome and disability of diabetic patients hospitalized for diabetic foot ulcers: A 6.5-year follow-up study. *Diabetes Care* 2008, 31, 1288–1292. [CrossRef]

77. Larsson, J.; Eneroth, M.; Aipelqvist, J.; Stenstrom, A. Sustained reduction in major amputations in diabetic patients: 628 amputations in 461 patients in a defined population over a 20-year period. *Acta. Orthop.* 2008, 79, 665–673. [CrossRef]

78. Goyal, R.; Singhai, M. Tuberculosis and non-diabetic hyperglycemia: A challenge to public health management. *Med. Hypotheses* 2013, 81, 1170–1177. [CrossRef]

79. Wang, W.T.; Lee, P.; Yeh, H.W.; Smirnova, I.V.; Choi, I.Y. Effects of acute and chronic hyperglycemia on the neurochemical profiles in the rat brain with streptozotocin-induced diabetes detected using in vivo 1 h MR spectroscopy at 9.4 t. *J. Neurochem.* 2012, 121, 407–417. [CrossRef]

80. Berlanga-Acosta, J.; Schultz, G.S.; Lopez-Mola, E.; Nieto, G.G.; Siverio, M.G.; Martinez, L.H. Glucose toxic effects on granulation tissue productive cells: The diabetics’ impaired healing. *BioMed Res. Int.* 2013, 2013, 256043. [CrossRef] [PubMed]

81. Jia, Y.N.; Xue, Z.H.; Wang, Y.J.; Lu, Y.P.; Li, R.L.; Li, N.N.; Wang, Q.R. Chemical structure and inhibition on α-glucosidase of polysaccharides from corn silk by fractional precipitation. *Carbohydr. Polym.* 2021, 252, 117185. [CrossRef] [PubMed]

82. Li, J.; Li, L.; Zhu, J.; Ai, Y.F. Utilization of maltogenic α-amylase treatment to enhance the functional properties and reduce the digestibility of pulse starches. *Food Hydrocoll.* 2021, 120, 106932. [CrossRef]

83. Bilhadj, S.; Hentati, O.; Elleki, A.; Hamden, K. Inhibitory activities of Ulva lactuca polysaccharides on digestive enzymes related to diabetes and obesity. *Arch. Physiol. Biochem.* 2013, 119, 81–87.

84. Li, Y.X.; Kim, S.K. Utilization of seaweed derived ingredients as potential antioxidants and functional ingredients in the food industry: An overview. *Food Sci. Biotechnol.* 2021, 20, 1461–1466. [CrossRef]

85. Blum, A.; Loerz, C.; Martin, H.J.; Staab-Weijnitz, C.A.; Maser, E. *Momordica charantia* extract, a herbal remedy for type 2 diabetes, contains a specific 11β-hydroxysteroid dehydrogenase type 1 inhibitor. *J. Steroid Biochem. Mol. Biol.* 2012, 128, 51–55. [CrossRef]

86. Iseli, T.; Oakhill, J.S.; Bailey, M.F.; Wee, S.; Walter, M.; Denderen, B.J.V.; Castelli, L.A.; Katsis, F.; Witters, L.A.; Stapleton, D.; et al. AMP-activated protein kinase subunit interactions. *J. Biol. Chem.* 2008, 283, 4799–4807. [CrossRef]

87. Bijland, S.; Mancini, S.J.; Salt, I.P. Role of amp-activated protein kinase in adipose tissue metabolism and inflammation. *Clin. Sci.* 2013, 124, 491–507. [CrossRef]

88. Zeng, W.F.; Yin, X.Z.; Jiang, Y.H.; Jin, L.T.; Liang, W. PPARα at the crossroad of metabolic–immune regulation in cancer. *FEBS J.* 2021, 2021, 1–14. [CrossRef]

89. Liu, Z.; Gong, J.; Huang, W.; Lu, F.; Dong, H. The effect of *Momordica charantia* in the treatment of diabetes mellitus: A review. *Evid-Based Compl. Alt.* 2021, 2021, 3796265. [CrossRef]

90. Pahlavani, N.; Roudi, F.; Zakarian, M.; Ferns, G.A.; Navashenag, J.G.; Mashkouri, A.; Ghayour-Mobarhan, M.; Rahimi, H. Possible molecular mechanisms of glucose- lowering activities of *Momordica charantia* (karela) in diabetes. *J. Cell. Biochem.* 2019, 120, 10921–10929. [CrossRef]
91. Sur, S.; Steele, R.; Aurora, R.; Varvares, M.; Schwetye, K.E.; Ray, R.B. Bitter Melon prevents the development of 4-NQO-induced oral squamous cell carcinoma in an immunocompetent mouse model by modulating immune signaling. *Cancer Prev. Res.* **2018**, *11*, 191–201. [CrossRef] [PubMed]

92. Peter, E.L.; Kasali, F.M.; Deyno, S.; Mtewa, A.; Nagendrappa, P.B.; Tolo, C.U.; Ogwang, P.E.; Sesaazi, D. *Momordica charantia* L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. *J. Ethnopharmacol.* **2019**, *231*, 311–324. [CrossRef] [PubMed]

93. Yokoyama, H.; Jensen, J.S.; Jensen, T.; Deckert, T. Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy. *J. Intern. Med.* **2010**, *237*, 519–523. [CrossRef] [PubMed]

94. Crook, M.A.; Pickup, J.C.; Lumb, P.J.; Georgino, F.; Webb, D.J.; Fuller, J.H. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: The eurodiab complications study. *Diabetes Care* **2001**, *24*, 316–322. [CrossRef]

95. Rahman, I.; Malik, S.A.; Bashir, M.; Khan, R.; Iqbal, M. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (*Momordica charantia*) and rosiglitazone (avandia) treatment. *Phytomedicine* **2009**, *16*, 401–405. [CrossRef]

96. Sukmawati, D.; Fujimura, S.; Jitsukawa, S.; Hirano, R.I.; Ishii, T.; Sato, T.; Hayashi, A.; Itoh, S.; Mizuno, H.; Daida, H.; et al. Oxidative stress tolerance of early stage diabetic endothelial progenitor cell. *Regen. Ther.* **2015**, *1*, 38–44. [CrossRef]

97. Kizub, I.V.; Klymenko, K.I.; Soloviev, A.I. Protein kinase C in enhanced vascular tone in diabetes mellitus. *Int. J. Cardiol.* **2014**, *174*, 230–242. [CrossRef]